Home > News > Dabur Pharma's Nanoxel receives DCGI approval
February 21st, 2008
Dabur Pharma's Nanoxel receives DCGI approval
Abstract:
Dabur Pharma announced that the Drug Controller General of India (DCGI) has approved its proprietary nanoparticle Paclitaxel formulation ‘Nanoxel' for additional indications of ovarian cancer, non-small cell lung cancer and AIDS related Kaposis's sarcoma. Speaking on the occasion Ajay Kumar Vij, CEO, Dabur Pharma said, "We are very pleased by DCGI's decision. Consistent with our mission of making cancer therapy available to more people, this approval will help a much larger patient population have access to a significantly safer and more convenient therapeutic alternative to conventional Paclitaxel." Nanoxel is a cremophor free polymeric nanoparticle formulation of Paclitaxel with no hypersensitivity reactions, which allows administration to patients without cumbersome pre-medication as is required with cremophor Paclitaxel.
Source:
expresspharmaonline.com
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Govt.-Legislation/Regulation/Funding/Policy
New discovery aims to improve the design of microelectronic devices September 13th, 2024
Physicists unlock the secret of elusive quantum negative entanglement entropy using simple classical hardware August 16th, 2024
Single atoms show their true color July 5th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||